A Minnesota device manufacturer’s quality agreement with a contract manufacturer was not up to the FDA’s standards and netted the firm a Form 483.

During a Feb. 27-March 5 inspection, the agency found issues with a quality agreement between Proximagen and a contract manufacturer, such as a lack of clarity over the contractor’s role in  customer complaint management and adverse event reporting.

The firm also did not designate a management representative to monitor and give updates on the facility’s quality system prior to August 2018.